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and/or from an employed person (33.0% versus 20.9%) and consumed more antide-
pressant drugs than patients with mild psoriasis (20.1% versus 7.8%). Mean individual 
cost of the disease was estimated to be a543/year/patient. CONCLUSIONS: This study 
is the ﬁrst in France to explore the impact of psoriasis on different perspectives. Our 
results show that psoriasis, particularly severe psoriasis, is a true burden for patients 
and impacts signiﬁcantly everyday life and patient economical resources.
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OBJECTIVES: The Dermatology Life Quality Index (DLQI; 10 items) is a generic 
dermatology health-related quality of Life (HRQoL) measure that is the most com-
monly used in dermatology. Despite its popularity little research has been conducted 
into the dimensionality of the questionnaire. The purpose of this study was to examine 
its scaling properties and establish whether it is unidimensional. METHODS: DLQI 
data were combined from two studies; one involving people with psoriasis and the 
other patients with atopic dermatitis. Item Response Theory was used to determine; 
overall ﬁt to the Rasch model, individual item ﬁt, targeting of scale to severity of 
respondents, functioning of response categories and the presence of Differential Item 
Functioning (DIF) by disease, age or gender. RESULTS: The sample included 146 
psoriasis patients (male 50%, mean age  44.2 range  17–83 years) and 146 atopic 
dermatitis patients (male 50%, mean age  45.5, range  20–82 years). The DLQI 
misﬁt the Rasch model (Chi2  63.38, df  40, p  0.01). Item 2 misﬁt the Rasch 
model and items 5 and 7 showed borderline misﬁt. Items 4, 6, 7, 8 and 9 had disor-
dered response thresholds indicating that these did not work in a logical way. Results 
showed a lack of spread in the measurement of HRQoL with too few items covering 
either milder or more severe levels of HRQoL. DIF by disease was shown in items 4 
and 7 and DIF by age in item 10. After removal of item 2 and rescoring the response 
categories the DLQI still misﬁt the Rasch model (Chi2  54.92., df  36, p  0.02). 
CONCLUSIONS: The results of the Rasch analysis showed there were several prob-
lems with the scaling properties of the DLQI and that little conﬁdence can be placed 
in raw scores generated from the scale. These problems need to be addressed before 
the QLDS can be considered a valid and useful outcome measure.
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OBJECTIVES: Many studies have observed the impact of physical appearance on 
Quality of life (QOL) but no speciﬁc instrument has been validated at an international 
level. Our objective was to develop such an instrument and to test its acceptability 
across a broad spectrum of cultures. The BeautyQol is a multidimensional, self-
 administered QOL questionnaire speciﬁc to cosmetology and physical appearance. 
METHODS: Semi directive interviews were conducted by clinical psychologists simul-
taneously in 10 countries in 309 subjects, men and women aged 18 to 70. In the 
second phase of development, an acceptability study in 13 countries representing 16 
cultures was conducted on 874 subjects in France, UK, Germany, Spain, Sweden, Italy, 
Russia, USA, Brazil, Japan, India (Hindi and English) China and South Africa (Zulu, 
Sotho and English). Statistical techniques include Kappa tests, Kendall correlations 
and Principal Component analyses RESULTS: From the item generation phase, 62 
questions were selected in describing major domains such as well being, self esteem, 
social life, love life, sexual life, conﬁdence, happiness, image, status, emotion, seduc-
tion, success, vitality, charisma, motivation, joy, fun, dignity, etc. General acceptability 
was very good according to the very low rate of no answer. Mean time duration was 
11 minutes to complete the 62 questions and 3 open questions (median: 9 min). Item   
reduction analyses led to a 48 questions. The next study currently underway is a global 
validation study involving a minimum of 3200 subjects worldwide. CONCLUSIONS: 
BeautyQol is the ﬁrst user-centered instrument speciﬁc in physical appearance that is 
being developed simultaneously in 13 countries. BeautyQol will be a valuable tool for 
national and international assessment in Dermatology, Cosmetic surgery, and Cosme-
tology. It is anticipated that BeautyQoL will be a useful instrument for the measure-
ment of QoL as affected by cosmetic products, techniques and agents that alter 
physical appearance of disease.
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OBJECTIVES: Despite increasing medical management of glaucoma, interventional 
procedures remain a substantial part. This study in 5 countries (France, Germany, 
Spain, Italy and England) aimed to estimate the annual number and costs of glaucoma 
operating procedures (surgery and laser). METHODS: Analysis of the available Diag-
nosis Related Groups (DRG) national health care databases was performed. Both 
inpatient stays and ambulatory care in hospitals were selected on the basis of speciﬁc 
DRG and diagnosis codes. Standard costs were applied. RESULTS: There are large 
variations in the number of glaucoma-related hospitalizations reported. Germany and 
France had the highest numbers at 46,191 and 19,784 respectively. England, Italy and 
Spain had 7,741, 4,135 and 2,210 stays annually in that order. Databases for Italy 
and Spain, however, were not nationally exhaustive. Of these ﬁgures, 26,827 procedures 
included combined cataract-glaucoma coding in Germany and 6,656 in France. These 
ﬁgures on in-hospital were over the last 3 year stable in Italy, France and England, 
Spain whereas there is an upward trend in Germany. Outpatient treatments were only 
reported in England, an additional 3,340 procedures. Severe or more complex proce-
dures involving surgery account for an estimated 46%, 93%, 67%, 23%, 89% in 
Germany, France, England, Italy, and Spain respectively. The corresponding average 
costs are a1972, a1469, a2246, a1946, and a2683. Of these. Day-Hospitalization in 
Italy account for 37% at a cost of 1085a while stays of less than 2 days in France 
account for 49% of all severe cases at a cost of 1009a. Total cost estimates are esti-
mated at 65 million a in Germany, 28 million a in France and 6 million £ in England. 
CONCLUSIONS: Available national health care databases have different coding.. Cost 
among severe interventions are comparable across countries. Short length of stay DRGs 
have a lower cost. Further studies including outpatient settings are needed.
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OBJECTIVES: To check clinical compliance with guidance speciﬁed by NICE Tech-
nology Appraisals 103 (etanercept & efalizumab1), 134 (inﬂiximab2) and 146 (adali-
mumab3). METHODS: A retrospective audit of medical records of patients treated 
with biologics for psoriasis, since issue of relevant NICE guidance in 6 UK Dermatol-
ogy centres. The audit was conducted between December 2008 and February 2009 in 
accordance with a standardised protocol and data collection form, with local manage-
ment approval to release anonymised data for pooled analysis. RESULTS: A total of 
173 courses of biologic treatment (in 149 patients) were included in the audit. PASI 
and DLQI were recorded at initiation of 96% (n  166) of treatments. Biologics were 
initiated for appropriately severe disease in 92% of cases (n  159) and only after 
failure, intolerance or contra-indication to standard systemic therapies in 98% 
(n  170) of cases. In 69% (n  120) of cases, PASI and DLQI were recorded at the 
appropriate review dates (10, 12 or 16 weeks, depending on biologic). Etanercept was 
prescribed at the licensed dose of 50 mg weekly in 92% of cases (n  120) but was 
discontinued appropriately in responders before week 24 in only 6.5% (n  3 of 45). 
Only 37% of cases with an inadequate response to biologics at the appropriate review 
date (n  50 of 135), had therapy withdrawn. CONCLUSIONS: In the 6 sites audited, 
compliance with national guidance was entirely appropriate for the commencement 
and dosing of biology therapy. However, the requirement to discontinue etanercept 
in responders was rarely followed. Similarly, discontinuation of biologics in non-
responders was not routine practice. These results indicate that despite guidance to 
the contrary etanercept is used continuously in practice in these specialist centres. This 
may indicate a reluctance of both patients and clinicians to withdraw an at least partly 
effective therapy in these refractory patients. Review of this aspect of NICE guidance 
may be warranted.
